Hypofractionation in Early Stage Non-Small Cell Lung Cancer.
Where this comes from
- Record sourced from PubMed, PMID 33610276.
- Also identified by DOI 10.1016/j.semradonc.2020.11.003.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Radiation treatment of early stage nonsmall cell lung cancer has evolved over the past 2 decades to progressively more hypofractionated treatment courses. Results comparable to surgical resection are seen with stereotactic body radiotherapy, which is now the standard of care for medically inoperable patients, and a treatment option for operable patients as well. Understanding of the optimal radiation dose and fractionation are evolving, especially for central tumors which have higher treatment toxicity than peripheral tumors.
Medical subject headings
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms
- Radiosurgery